Multiple sclerosis Flashcards

1
Q

A 39 year old femal presents with a burning sensation affecting her arms and legs over the last few weeks. Additionally, she has noted her vision has become blurry, and finds it difficult to discern the colour red.

On examination she has 3/6 vision in her left eye. The right eye is normal.

What is the diagnosis?

A

Optic neuritis

From this presentation alone, the diagnosis of Multiple Sclerosis cannot be made as the lesion must be disseminated in time and space. This lesion is disseminated in space but not in time.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Causes of optic neuritis

A
  • Demyelination eg MS
  • Infection eg Lyme’s disease
  • SLE
  • Sarcoidosis
  • Vasculitides
  • Idiopathic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is optic neuritis?

A

Inflamation of the optic nerve

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Symptoms of optic neuritis

A
  • Blurred vision
  • Loss of red colour vision
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Define multiple sclerosis

A

Chronic autoimmune disorder of the CNS resulting in demyelination of white matter.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What cell is affected in MS? Why is this significant?

A

Oligodendrocytes

They only exist in the central nervous system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Risk factors for multiple sclerosis

A
  • Age: 20-40 years old
  • Female: 3 x more common
  • Family history: HLA-DR2
  • Autoimmunity
  • Vitamin D deficiency
  • EBV infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which is the most common type of MS?

A

Relapsing remitting

About 85% of patients have this form at disease onset

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the types of multiple sclerosis?

A
  • Relapsing remitting
    • Episodic flare-ups (may last days, weeks or months), separated by periods of remission
    • After each successive relapse, disability increases
    • 60% of patients develop secondary progressive MS within 15 years
  • Secondary progressive
    • Initially, the disease starts with a relapsing-remitting course, but then symptoms get progressively worse with no periods of remission
    • Associated with co-ordination difficulties and bladder/bowel issues
  • Primary progressive
    • Symptoms get progressively worse from disease onset with no periods of remission
    • Accounts for 10% of cases and is more common in older patients
  • Progressive relapsing
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Symptoms of multiple sclerosis

A
  • Blurred vision and red desaturation
  • Numbness, tingling and other strange sensations
  • Weakness
  • Bowel and bladder dysfunction
  • Uhtoff’s phenomenon: worsening of symptoms following a rise in temperature, such as a hot bath
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Signs of multiple sclerosis

A
  • Visual
    • Optic neuritis
      • Pale optic disc and inability to see red
      • Relative afferent pupillary defect
    • Unilateral or bilateral internuclear opthalmoplegia
  • Sensory loss: due to demyelination of spinothalamic or dorsal columns
  • Upper motor neuron signs with spastic paraparesis are common
  • Cerebellar signs such as ataxia and tremor (usually in a relapse)
  • Lhermitte’s phenomenon: electric shock sensation on neck flexion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is demyelinated in internuclear opthalmoplegia?

A

Medial longitudinal fasiculus (MLF)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How does internuclear opthalmoplegia present?

A
  • Can be unilateral or bilateral
  • For example, with right sided INO, i.e. a right MLF lesion, the patient cannot adduct their right eye when looking left
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What diagnostic criteria is used to diagnose MS?

A

McDonald criteria

Diagnosis is based on:

  • 2 or more relapses AND EITHER
    • Objective clinical evidence of 2 or more lesions OR
    • Objective clinical evidence of one lesion WITH a reasonable history of a previous relapse
  • ‘Objective evidence’ is defined as an abnormality on neurological exam, MRI or visual evoked potentials
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Investigations for MS

A
  • MRI brain and spine:
    • ​Demyelinating plaques appear as high signal on T2 MRI
    • New lesions: enhance with gadolinium contrast
    • Old lesions: do not enhance
  • Lumbar puncture: oligoclonal IgG bands in the CSF and not in the serum
  • Visual evoked potentials: delayed velocity but a normal amplitude
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Define relapse in MS

A

Onset of new symptoms, or the worsening of pre-existing symptoms, lasting for more than 24 hours in the absence of any other cause after a stable period of at least a month.

17
Q

Management of a relapse of MS

A
  • Steroids: reduce relapse duration but do not influence whether the patient returns to their baseline
    • Oral or IV methylprednisolone is first-line and is usually continued for 5 days
    • Steroids reduce relapse duration by 13 days
  • Plasma exchange: consider for sudden, severe relapses not improving on steroids
18
Q

When do we give maintainance therapy to patients with MS?

A
  • Indicated in certain patients who have had:
    • 2 or more relapses in the last 2 years
    • New MRI lesions without clinical relapse
19
Q

What does maintainance therapy for MS look like?

A

DMARDs: reduce the rate of relapse

  • Beta-interferon: anti-inflammatory effect (reduces relapse but not progression)
  • Monoclonal antibodies: (reduce relapse rate and progression) such as:
    • alemtuzumab (anti-CD52) and natalizumab (anti-α4𝛃1-integrin)
  • Glatiramer acetate: immunomodulator drug which acts as a ‘decoy’
  • Fingolimod: a sphingosine-1-phosphate receptor modulator that keeps lymphocytes in lymph nodes so they can’t cause inflammation
20
Q

Complications of MS

A
  • Mental health issues: depression, emotional lability
  • Genitourinary: urinary tract infections, urinary retention and incontinence
  • Constipation
  • Erectile dysfunction
  • Visual impairment
  • Mobility impairment: offer physiotherapy, orthotics and other mobility aids
  • Fatigue
  • Spasticity
21
Q

Management of fatigue in MS

A

Investigate other causes (eg anaemia), CBT and consider amantadine

22
Q

Management of spasticity in MS

A

Physiotherapy, avoid triggers, baclofen or gabapentin are first line

23
Q

Management of MS related emotional lability

A

Amitriptyline

24
Q

Management of bladder dysfunction in MS

A

Perform a bladder ultrasound

  • Significant residual volume: intermittent self catheterisation
  • Insignificant residual volume: consider an anticholinergic (eg oxybutynin)
25
Q

Differential diagnosis for multiple sclerosis

A
  • Neuromyelitis Optica
    • Primarily affects the optic nerves and spinal cord
    • Antibodies against Aquaporin 4
  • SLE
  • Sarcoidosis
  • B12 deficiency